JW Pharmaceutical Releases Results of Statin Treatment Awareness Survey

On May 28, JW Pharmaceutical announced the results of its "Statin Treatment Awareness Survey" conducted with 500 patients with dyslipidemia and 329 healthcare professionals. According to the survey, the main barriers to continued statin therapy were differences in perception regarding the necessity of treatment and concerns about side effects.


Dyslipidemia requires lifelong management, but 50.8% of patients responded that they could stop taking medication once their low-density lipoprotein cholesterol (LDL-C) levels normalized or after a certain period of time. There was a significant perception gap regarding the impact of treatment discontinuation on life expectancy: 59.3% of healthcare professionals said it would have a very significant effect, whereas only 18.6% of patients agreed.

Three Out of Ten Dyslipidemia Patients Cite "Concerns About Side Effects" View original image

Three out of ten patients reported hesitating or refusing to take statins, with the primary reason being concerns about side effects (50.1%). The types of side effects that caused concern differed between groups. Healthcare professionals most frequently cited muscle-related side effects (77.7%), while patients were most anxious about elevated liver enzyme levels (52.6%) and blood sugar-related side effects (33.0%).


In particular, information regarding blood sugar side effects had a direct impact on actual treatment. Among patients who became concerned after encountering such information, 35.2% reported delaying the start of treatment or discontinuing medication. In contrast, only 11% of patients were aware that there are alternative statin treatment options available that can be discussed with healthcare professionals in case of concerns about blood sugar changes.


The survey found that both patients and healthcare professionals agreed that explanations from healthcare professionals were the most trusted and common source of statin information. More than 80% of both groups recognized the need for improved communication to bridge the perception gap. Based on these findings, JW Pharmaceutical plans to launch the "Dangbu, Statin" campaign to reduce informational disparities between patients and healthcare professionals and to support proper disease management.



A JW Pharmaceutical representative stated, "Through this survey, we confirmed the perception gap between patients and healthcare professionals regarding the need for continued statin therapy and concerns about side effects, and found that both sides agree on the importance of information sharing and communication." The representative added, "Through the 'Dangbu, Statin' campaign, we will continue activities to close the information gap and support consistent, lifelong management for patients with dyslipidemia."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing